Drug intelligence / Profile preview

compound 6h

Development stage: Preclinical
Modality: Small Molecules

Overview

Compound 6h is an experimental **quinazolinone-derived small molecule** reported in a preclinical medicinal chemistry study as a potential multitarget therapy for **Alzheimer's disease**. In the cited work, compound 6h showed promising **anti-acetylcholinesterase**, **anti-inflammatory**, **antioxidant**, and **neuroprotective** activity in a scopolamine-induced mouse model, with behavioral improvement in the Morris water maze and reduction of hippocampal inflammatory markers. The publication indicates intended engagement of **acetylcholinesterase** based on enzymatic testing and molecular docking, but the precise chemical name, developer, and any formal clinical development program were not identified from the provided source.

Other names: quinazolinone derivative 6h

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on compound 6h.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 6h.

Explore the full profile